all report title image

U.S. Liposomal Doxorubicin Market, By Drug Type (Branded, Generic), By Cancer Type (Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, Others), By Geography (U.S)

  • Published In : Jul 2026
  • Code : CMI4508
  • Pages :259
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
  • 역사적 분포 범위 : 2020 - 2024
  • 기준 연도 : 2025
  • 예상 연도 : 2026
  • 예측 기간 : 2026 - 2033
Ingographics Image

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Doxorubicin acts by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal delivery of doxorubicin HCL (Hydrochloride) improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Some side effects of using Doxil or doxorubicin hydrochloride liposome include low blood counts, hand-to-foot syndrome (palmar-plantar erythrodysesthesia), mouth sores, infusion-related side effects: shortness of breath, facial swelling, headache, back pain, flushing, tightness in the chest and throat, and/or low blood pressure.

Market Dynamics

The increasing prevalence of cancer is expected to drive demand for liposomal doxorubicin for treatment of the disease and aid in growth of the U.S. liposomal doxorubicin market. For instance, according to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., and accounted for nearly one out of four deaths. Moreover, according to National Cancer Institute, in 2019, around 1.8 million people were diagnosed with cancer in the U.S., and around 276,480 women and 2,670 men were diagnosed with breast cancer.

Key features of the study

  • This report provides in-depth analysis of the U.S. liposomal doxorubicin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. liposomal doxorubicin market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. liposomal doxorubicin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. liposomal doxorubicin market

Market Segmentation

  • By Drug Type (Revenue, USD Mn, 2021-2033)
    • Branded
    • Generic
  • By Cancer Type (Revenue, USD Mn, 2021-2033)
    • Ovarian Cancer
    • AIDS-related Kaposi’s Sarcoma
    • Multiple Myeloma
    • Others
  • By Region (Revenue, USD Mn, 2021-2033)
    • California
    • Texas
    • Florida
    • New York
    • Pennsylvania
    • Illinois
    • Ohio
    • Georgia
    • North Carolina
    • Michigan
    • New Jersey
    • Virginia
    • Washington
    • Arizona
    • Others
  • Key Players
    • Johnson & Johnson
    • Baxter International Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Reddy’s Laboratories, Inc.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Cancer Type
      • Market Snapshot, By State
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Product Approval
    • Collaboration/Merge/Acquisition
    • Regulatory Landscape
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Epidemiology
    • Robust Pipeline Analysis
  4. U.S. Liposomal Doxorubicin Market, By Drug Type, 2021 – 2033, (USD Million)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Branded
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
    • Generic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
  5. U.S. Liposomal Doxorubicin Market, By Cancer Type, 2021 – 2033, (USD Million)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022 – 2033
      • Segment Trends
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
    • AIDS-related Kaposi’s Sarcoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
    • Multiple Myeloma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
  6. U.S. Liposomal Doxorubicin Market, By State, 2021 – 2033, (USD Million)
    • Introduction
      • Market Share Analysis, By State, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For States, 2022–2033
      • State Trends
    • California
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Texas
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Florida
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • New York
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Pennsylvania
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Illinois
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Ohio
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Georgia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • North Carolina
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Michigan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • New Jersey
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Virginia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Washington
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Arizona
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Million)
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profile
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Baxter International Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Dr. Reddy’s Laboratories, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us
  9.  
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.